Cancer vaccines.
Durrant
L G
LG
CRC Department of Clinical Oncology, City Hospital, Nottingham, UK.
Spendlove
I
I
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000951:Antigens, Neoplasm; D004273:DNA, Neoplasm / Q000276:immunology; D006360:Heat-Shock Proteins / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active; D009077:Mucins / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009857:Oncogenes; D013601:T-Lymphocytes / Q000276:immunology; D014765:Viral Vaccines / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D000951:Antigens, Neoplasm; D004273:DNA, Neoplasm; D006360:Heat-Shock Proteins; D015395:Histocompatibility Antigens Class I; D009077:Mucins; D014765:Viral Vaccines